11 recruiting, 7 completed, 3 not yet recruiting, 2 unknown. 9 Phase 2, 8 Phase 1, 4 Not applicable, 3 Phase 3.
Follow Gall Bladder Cancer: new trials by email Literature Review of Gall Bladder Cancer trials Research Report on Gall Bladder Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IKS04 Regimen in Advanced Solid Tumors That Express CA242 IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody - Colorectal Cancer, Gastro Esophageal Junctional Cancer | Phase 1 | Not yet recruiting | Iksuda Therapeutics Ltd. | 120 | 2026-11-01 | 2026-07-31 |
| TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World Cohort Biliary Tract Cancer (BTC), Biliary Tract Cancer (CCA) | Not yet recruiting | Aarhus University Hospital | 300 | 2026-03-15 | 2026-03-06 | |
| Distance-Based Exercise to Preserve Function and Prevent Disability Exercise intervention, Telemedicine, Aerobic Exercise Intervention - Localized Malignant Solid Neoplasm, Anal Cancer | Not applicable | Recruiting | Alliance for Clinical Trials in Oncology | 104 | 2026-02-11 | 2026-10-02 |
| Study of ACC-1898 in Adult Participants With Advanced Solid Tumors ACC-1898 - Hepatocellular Carcinoma, Renal Cell Carcinoma | Phase 1 | Not yet recruiting | AccSalus Biosciences, Inc. | 40 | 2026-01-01 | 2025-11-28 |
| DESTINY-PANTUMOUR04 Trastuzumab deruxtecan - Adenocarcinoma (NOS), Anal Cancer | Recruiting | AstraZeneca | 100 | 2025-09-18 | 2026-09-25 | |
| Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer PD-1/CTLA-4 Dual Functional Antibody, Gemcitabine, Cisplatin, Anlotinib - Bile Duct Carcinoma, Gall Bladder Cancer | Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | 60 | 2025-06-01 | 2025-06-17 |
| Prospective Evaluation of 68Ga-FAPI PET in Biliary Cancers gallium-68-Fibroblast Activation Protein Inhibitor - Gall Bladder Cancer, Intrahepatic Cholangiocarcinoma (Icc) | Recruiting | Tata Memorial Centre | 60 | 2024-09-25 | 2026-01-13 | |
| Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer chemotherapy with gemcitabine and oxaliplatin; small molecure TKI lenvatinib; immune-checkpoint inhibitor toripalimab. - Intrahepatic Cholangiocarcinoma (Icc), Gall Bladder Cancer | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 33 | 2024-09-01 | 2025-02-28 |
| Radiation Therapy in Unresectable Gall Bladder Cancer Systemic therapy (Gemcitabine plus Cisplatin), RT, Systemic therapy (Gemcitabine plus oxaliplatin) - Gall Bladder Cancer | Phase 2 / Phase 3 | Recruiting | Tata Memorial Centre | 249 | 2024-03-07 | 2025-04-11 |
| Robotic-assisted Contra Open Resection for Suspected or Confirmed Gallbladder Cancer (ROBOCOP) Robotic-assisted radical cholecystectomy, Open radical cholecystectomy - Gall Bladder Cancer | Not applicable | Recruiting | Karolinska University Hospital | 94 | 2024-01-23 | 2025-09-05 |
| Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG) Ablative local therapy - Small Bowel Cancer, Colorectal Cancer | Not applicable | Recruiting | University of California, Davis | 300 | 2023-10-05 | 2026-07-02 |
| Primary Percutaneous Stenting Above the Ampulla Versus Endoscopic Drainage for Unresectable Malignant Hilar Biliary Obstruction Primary percutaneous stenting (PPS), Endoscopic biliary drainage - Cholangiocarcinoma Non-resectable, Gall Bladder Cancer | Phase 3 | Enrolling by invitation | Erasmus Medical Center | 148 | 2023-08-09 | 2024-11-04 |
| A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors certepetide, Durvalumab, Cisplatin - Cholangiocarcinoma, Gallbladder Cancer | Phase 2 | Completed | Lisata Therapeutics, Inc. | 66 | 2023-05-13 | 2026-09-28 |
| A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) CTX-009, Paclitaxel - Biliary Tract Cancer, Cholangiocarcinoma | Phase 2 / Phase 3 | Active not recruiting | Compass Therapeutics | 168 | 2023-01-09 | 2026-09-02 |
| Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types Atezolizumab, Tivozanib - Bile Duct Cancer, Gall Bladder Cancer | Phase 1 / Phase 2 | Recruiting | University of Florida | 29 | 2021-12-07 | 2026-07-13 |
| A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection S-1, Capecitabine - Biliary Tract Neoplasms, Recurrence | Unknown | Fudan University | 160 | 2020-11-01 | 2022-08-18 | |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) rezatapopt, pembrolizumab - Advanced Solid Tumor, Advanced Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | PMV Pharmaceuticals, Inc | 300 | 2020-10-29 | 2026-10-02 |
| Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab Bevacizumab, Dasatinib, Fluorouracil - Advanced Colorectal Carcinoma, Metastatic Colorectal Carcinoma | Phase 1 | Completed | Anne Noonan | 9 | 2020-09-02 | 2024-12-27 |
| A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering Cyclophosphamide, Fludarabine, Tumor-Infiltrating Lymphocytes (TIL) - Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms | Phase 1 / Phase 2 | Completed | Intima Bioscience, Inc. | 23 | 2020-05-15 | 2026-02-23 |
| A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening Gall Bladder Cancer, Intrahepatic Cholangiocarcinoma (Icc) | Recruiting | Yingbin Liu, MD, PhD, FACS | 1800 | 2020-01-01 | 2025-09-16 |
Showing 20 of 27. Sign in to see all of them.
Gallbladder Neoplasms (27) · Cholangiocarcinoma (11) · Biliary Tract Neoplasms (9) · Pancreatic Neoplasms (9) · Stomach Neoplasms (9) · Esophageal Neoplasms (7) · Bile Duct Neoplasms (6) · Colonic Neoplasms (6) · Colorectal Neoplasms (6) · Prostatic Neoplasms (5) · Anus Neoplasms (4) · Breast Neoplasms (4) · Head and Neck Neoplasms (4) · Neoplasms (4) · Ovarian Neoplasms (4)
Biliary Tract Diseases (27) · Digestive System Diseases (27) · Digestive System Neoplasms (27) · Gallbladder Diseases (27) · Neoplasms by Site (27) · Neoplasms (23) · Biliary Tract Neoplasms (18) · Neoplasms by Histologic Type (18) · Neoplasms, Glandular and Epithelial (17) · Adenocarcinoma (15) · Carcinoma (15) · Gastrointestinal Diseases (12) · Intestinal Diseases (12) · Intestinal Neoplasms (12) · Colonic Diseases (11)
Oxaliplatin (7) · Gemcitabine (5) · Cisplatin (4) · Fluorouracil (4) · Leucovorin (4) · Capecitabine (2) · durvalumab (2) · 130-nm albumin-bound paclitaxel (1) · 3-(3'-adamantan-1-yl-4'-methoxybiphenyl-4-yl)-2-propenoic acid (1) · Accelerometry (1) · Anthracyclines (1) · Antimetabolites (1) · Bevacizumab (1) · Camptothecin (1) · Cyclophosphamide (1)
Tata Memorial Centre (2) · Aarhus University Hospital (1) · AccSalus Biosciences, Inc. (1) · Alliance for Clinical Trials in Oncology (1) · Andes Biotechnologies (1) · Anne Noonan (1) · AstraZeneca (1) · Compass Therapeutics (1) · Daniel Bernstein (1) · Erasmus Medical Center (1) · First Affiliated Hospital of Zhejiang University (1) · Fudan University (1) · Iksuda Therapeutics Ltd. (1) · Intima Bioscience, Inc. (1) · Karolinska University Hospital (1)
United States (12) · China (4) · India (2) · Italy (2) · Sweden (2) · Australia (1) · Chile (1) · Denmark (1) · France (1) · Germany (1) · Netherlands (1) · Singapore (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Anders Johnsson, MD, PhD (1) · Anne M Noonan, MBBChBAO, MSc (1) · Bernadita Mendez, PhD (1) · Christian Sturesson, PhD (1) · Cynthia Sirard, MD (1) · Daniel Bernstein (1) · Dr.Shraddha Patkar (1) · Edward Kim, MD, PhD (1) · Emil Lou, MD, PhD (1) · Haruka Itakura (1) · James O'Leary, MD (1) · Jennifer Ligibel, MD (1) · Karen-Lise Garm Spindler, Professor, MD, PhD (1) · Kathryn Schmitz, MD (1) · Kristen K Buck, MD (1)
PMID 32183229, PMID 33142018, PMID 33259690, PMID 34439284, PMID 36372281, PMID 36399037, PMID 38477985, PMID 38861293, PMID 40068597, PMID 40315882, PMID 40346549, PMID 40543428, PMID 40621784, PMID 40673842, PMID 40812353, PMID 40932470, PMID 41740031
2023 (1), P30CA093373 (1)